Exact Sciences Corp (EXAS)
105.51
+1.30 +1.25%
NASDAQ
Aug 4, 11:39
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 1.712B |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -5.46 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -864.77M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 73.78% |
| Profit Margin (Quarterly) | -40.69% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 18.14B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 9.980 |
| PE Ratio | -- |
| Price to Book Value | 5.097 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.6182 |
| Free Cash Flow (Quarterly) | 15.75M |
| Return on Equity | Upgrade |
View All EXAS News
News
-
WireHeadlineTime (ET)
-
SA Breaking News08/03 13:54
-
Yahoo07/30 06:20
-
MT Newswires07/29 17:42
-
Yahoo07/29 11:14
-
MT Newswires07/29 10:54
-
MT Newswires07/29 10:54
-
MT Newswires07/29 09:54
-
MT Newswires07/29 04:55
-
Yahoo07/29 02:02
-
Yahoo07/28 17:55
-
MT Newswires07/28 17:49
-
MT Newswires07/28 16:46
-
Yahoo07/28 16:42
-
MT Newswires07/28 16:22
-
MT Newswires07/28 16:22
-
PR Newswire07/28 16:05
-
MT Newswires07/28 12:05
-
Yahoo07/21 15:02
-
Yahoo07/19 09:54
-
Yahoo07/19 05:20
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 10/29/2021 | Earnings Results | Q3 2021 Earnings Results |
| 10/29/2021 17:00 EST | Earnings Calls | Q3 2021 Earnings Call |
| 07/28/2021 | Earnings Results | Q2 2021 Earnings Results |
| 07/28/2021 17:00 EST | Earnings Calls | Q2 2021 Earnings Call |
| 05/04/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/04/2021 17:00 EST | Earnings Calls | Q1 2021 Earnings Call |
| 02/16/2021 | Earnings Results | Q4 2020 Earnings Results |
| 02/16/2021 17:00 EST | Earnings Calls | Q4 2020 Earnings Call |
| 10/29/2020 17:00 EST | Earnings Calls | Q3 2020 Earnings Call |
| 10/29/2020 | Earnings Results | Q3 2020 Earnings Results |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
- URL: https://www.exactsciences.com
- Investor Relations URL: https://investor.exactsciences.com/investor-relations/default.aspx
- HQ State/Province: Wisconsin
- Sector: Healthcare
- Industry: Diagnostics & Research
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Oct. 29, 2021
- Last Earnings Release: Jul. 28, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 105.51 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| ARKG | ARK Genomic Revolution ETF | 5.03% |
| DFRIX | Delaware Smid Cap Growth R | 4.66% |
| BBH | VanEck Vectors Biotech ETF | 4.36% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.21% |
| ETCGX | Eventide Gilead C | 2.98% |
| ARKK | ARK Innovation ETF | 2.92% |
| EARK.NO | Emerge ARK Global Disruptive Innovt ETF | 2.86% |
| GOFFX | Invesco Global Opportunities R5 | 2.52% |
| TRUZX | T. Rowe Price New Horizons Z | 2.02% |
| PAGSX | T. Rowe Price Global Stock Adv | 1.91% |
| APDMX | Artisan Mid Cap Advisor | 1.82% |
| HQH | Tekla Healthcare Investors | 1.07% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- EXAS Tweets Stocktwits
Advertisement
